Looking at 2025, Health: Breakthroughs of hope and promise
Weight-loss treatments are on the cusp of a revolution, and could benefit large numbers of Indians after the main patent ...
The Zepbound Shortage Is Over — Here's What to Expect if You've Been Using a Compounding Pharmacy
Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...
'What a difference a year makes': Stocks in this sector are set to surge in 2025 after a disappointing year, Citi says
Citi analysts forecast 19% earnings growth for the healthcare sector in 2025 amid improving fundamentals and a boom in weight loss drugs.
Tyler Morning Telegraph16h
Medicaid Now Covers GLP-1s for Obesity in Texas
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
Hastings Tribune16h
Kansas Medicaid Spend on GLP-1s for Obesity up 97% Year-Over-Year
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
The Mountaineer16h
North Carolina Medicaid Spend on GLP-1s for Obesity up 111% Year-Over-Year
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
Health risks from wildfire smoke linger 3 years after Marshall Fire
In a new study, researchers examined the health effects people experienced when they returned to still-standing homes after ...
Hosted on MSN17h
Pharma Stock Roundup: NVO's Obesity Study Failure, FDA Nod to PFE, LLY
Novo Nordisk NVO announced disappointing data from a phase III study on a novel obesity candidate. The FDA approved Eli Lilly ...
Better Buy: Eli Lilly vs. Novo Nordisk. The Answer Is Becoming Abundantly More Clear.
Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...